Genentech Links With Arvinas On Protein Degradation
This article was originally published in Scrip
Executive Summary
Genentech, a member of the Roche Group, provided an undisclosed upfront payment and may invest more than $300m in milestone fees to use PROTAC, Arvinas Inc.'s targeted protein degradation technology, to create novel drugs against multiple disease targets.